Treatment of treatment-resistant autoimmune blistering skin disorders with rituximab

British Journal of Dermatology

Volumn 160, Issue 6, 2009, Pages 1359-1361

  Jensen, A O ^a   Moller B K ^a   Vangkilde, A ^a   Mark, B ^a   Obitz, E R ^a   Kragballe, K ^a   Iversen, L ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Autoimmune blistering skin disorders; Efficacy; Rituximab

Indexed keywords

RITUXIMAB;

ADULT; AGED; AUTOIMMUNE SKIN DISEASE; BLISTER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EPIDERMOLYSIS BULLOSA ACQUISITA; FEMALE; HUMAN; LETTER; MALE; PARANEOPLASTIC PEMPHIGUS; PEMPHIGUS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VEGETANS; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; SKIN DISEASES, VESICULOBULLOUS; TREATMENT OUTCOME;

EID: 66149148730     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09132.x     Document Type: Letter

References (10)

1. Agarwal M, Walia R, Kochhar AM, Chander R. Pemphigus Area and Activity Score (PAAS) - a novel clinical scoring method for monitoring of pemphigus vulgaris patients. Int J Dermatol 1998 37 : 158 60.
2. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003 14 : 520 35.
3. Cooper HL, Healy E, Theaker JM, Friedmann PS. Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (rituximab). Clin Exp Dermatol 2003 28 : 366 8.
4. Herrmann G, Hunzelmann N, Engert A. Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Br J Dermatol 2003 148 : 602 3.
5. Virgolini L, Marzocchi V. Anti-CD20 monoclonal antibody (rituximab) in the treatment of autoimmune diseases. Successful result in refractory pemphigus vulgaris: report of a case. Haematologica 2003 88 : ELT24.
6. Espana A, Fernandez-Galar M, Lloret P et al. Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations. J Am Acad Dermatol 2004 50 : 974 6.
7. Dupuy A, Viguier M, Bedane C et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol 2004 140 : 91 6.
8. Faurschou A, Gniadecki R. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris. Int J Dermatol 2008 47 : 292 4.
9. Eming R, Nagel A, Wolff-Franke S et al. Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol 2008 128 : 2850 8.
10. Mouquet H, Musette P, Gougeon ML et al. B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol 2008 128 : 2859 69.